A rare-disease case described refractory seizures during multidrug treatment. Later improvement followed additional medicines, making a single-drug efficacy conclusion inappropriate.
The patient had developmental delay, hypotonia, an MYO5A mutation, and an additional chromosome deletion. Seizures persisted despite treatment including clobazam, zonisamide, a cannabinoid preparation, and ketogenic diet.
After lacosamide and levetiracetam were added, reported seizure frequency decreased from about ten to five daily. The report also reviewed seizure presentations across Griscelli syndrome types.
The case involved severe underlying disease and multiple concurrent treatments. It cannot determine whether clobazam provided partial benefit, no benefit, or a different effect than another drug would have produced.
A reduction after adding two agents likewise does not isolate either agent’s contribution. Forensic or clinical summaries should preserve the sequence, residual seizure burden, and genetic context. The report does not establish a preferred benzodiazepine strategy for Griscelli syndrome or a general rate of clobazam treatment failure.
Original analysis of the supplied journal article, identified as PMC8109045.